Scarica l'app Stockscreener
0.5863
2.29%
0.0131
Precedente Chiudi:
$0.5732
Aprire:
$0.5839
Volume 24 ore:
5.09M
Relative Volume:
0.93
Capitalizzazione di mercato:
$176.89M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.7817
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
+1.09%
1M Prestazione:
+22.20%
6M Prestazione:
-45.21%
1 anno Prestazione:
-31.81%
Intervallo 1D:
$0.57
$0.6049
Intervallo di 1 settimana:
$0.5321
$0.6049
Portata 52W:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5863 | 177.74M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Predicting Sangamo Therapeutics Inc. trend using moving averages2025 Trading Volume Trends & Safe Entry Zone Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Market Volume Report & Scalable Portfolio Growth Ideas - Newser
Long term hold vs stop loss in Sangamo Therapeutics Inc.Quarterly Profit Review & Real-Time Stock Entry Alerts - Newser
Will Sangamo Therapeutics Inc. stock recover after recent dropBuy Signal & Free Daily Entry Point Trade Alerts - Newser
Sangamo Therapeutics Inc. stock prediction for this weekJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Will Sangamo Therapeutics Inc. outperform the marketJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Custom strategy builders for tracking Sangamo Therapeutics Inc.July 2025 Market Mood & Precise Entry and Exit Recommendations - Newser
Risk adjusted return profile for Sangamo Therapeutics Inc. analyzed2025 Bull vs Bear & Reliable Price Breakout Signals - Newser
Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to “Hold” - Defense World
HC Wainwright Analysts Raise Earnings Estimates for SGMO - Defense World
How Sangamo Therapeutics Inc. stock performs during market volatilityQuarterly Market Summary & Verified Swing Trading Watchlist - Newser
Sangamo rises after trial data for Fabry disease therapy - MSN
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
What Makes Sangamo (SGMO) a New Buy Stock - sharewise.com
Analyzing Sangamo Therapeutics (NASDAQ:SGMO) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Has Sangamo Therapeutics Inc. formed a bullish divergence2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
What to expect from Sangamo Therapeutics Inc. in the next 30 daysWeekly Profit Report & Weekly Consistent Profit Watchlists - Newser
Sangamo Therapeutics (SGMO.O) Surges 11.3% on Strong KDJ Signal Amid Mixed Biotech Sector Moves - AInvest
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSwing Gain Strategy with Entry Forecast - Newser
Sangamo Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates - MSN
Will Sangamo Therapeutics Inc. rebound enough to break evenJuly 2025 Pullbacks & Safe Entry Point Identification - Newser
Transcript : Sangamo Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Sangamo: Q2 Earnings Snapshot - Greenwich Time
Earnings call transcript: Sangamo Therapeutics Q2 2025 earnings miss, stock drops - Investing.com Australia
Sangamo Q2 2025 slides: Neurology pipeline advances amid financial challenges - Investing.com Australia
Sangamo Therapeutics shares fall 4.55% premarket after Q2 revenue misses estimates. - AInvest
Sangamo Therapeutics Inc (SGMO) Q2 2025 Earnings Call Highlights: Promising Fabry Disease ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics 2025 Q2 Earnings Improved Losses Despite Revenue Surge - AInvest
Sangamo Therapeutics Reports Strong Q2 2025 Results - TipRanks
Sangamo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sangamo Therapeutics Q2 Misses Revenue Estimates and Reiterates 2025 Guidance — What This Means for Its Strategic Path Forward - AInvest
Sangamo Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Sangamo Therapeutics Q2 revenue misses estimates - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - Yahoo Finance
Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Thursday - Defense World
Sangamo Therapeutics Announces Second Quarter 2025 Earnings CallLife Science Industry News - Zenopa
GSA Capital Partners LLP Boosts Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedHigh-yield market plays - Jammu Links News
What are Sangamo Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
How does Sangamo Therapeutics Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
Why is Sangamo Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on top-performing stocks - Jammu Links News
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):